Hibbins M, Inutsuka S, Chapman J R
Department of Renal Medicine, Westmead Hospital, Sydney, NSW Australia.
Transpl Immunol. 1993;1(1):66-71. doi: 10.1016/0966-3274(93)90061-c.
In vitro inhibition of human peripheral blood mononuclear cell (PBMC) proliferation by immunosuppressive drugs has been shown to correlate with clinical outcomes in kidney transplant patients. The aim of our study was to analyse the degree of variability of in vitro interactions of FK506 (FK) with combinations of cyclosporin A (CyA), methylprednisolone (MP), 6-mercaptopurine (6ME), and mycophenolic acid (MPA) using phytohaemagglutinin (PHA) stimulated PBMCs. Our hypotheses were: that a wide range of interindividual variation would be detected; and that certain combinations of drugs would have a synergistic inhibitory effect on PHA stimulated PBMCs. Cells were cultured in supplemented RPMI 1640 for 65 hours at 37 degrees C in humidified 5% CO2 - 95% air and proliferative responses measured by 3H-thymidine incorporation over a further 24 hours. Inhibition of PBMC proliferation was assessed over 10 FK concentrations ranging from 1 x 10(-8) to 10 micrograms/ml using both volunteer controls (n = 51) and dialysis patients (n = 23). A wide range of interindividual variability of FK inhibition occurred throughout the range of FK concentrations tested, becoming less variable at the higher concentrations. The interactions of FK with CyA, MP, 6ME and MPA were assessed using PBMCs from 12 volunteer controls. For FK at 1 x 10(-8) micrograms/ml; CyA, MP, 6ME and MPA were used at 0.01 microgram/ml. For FK at 1 x 10(-7) micrograms/ml; CyA, MP, 6ME and MPA were used at 0.1 microgram/ml.(ABSTRACT TRUNCATED AT 250 WORDS)
免疫抑制药物对人外周血单个核细胞(PBMC)增殖的体外抑制作用已被证明与肾移植患者的临床结果相关。我们研究的目的是使用植物血凝素(PHA)刺激的PBMC分析FK506(FK)与环孢素A(CyA)、甲泼尼龙(MP)、6-巯基嘌呤(6ME)和霉酚酸(MPA)组合的体外相互作用的变异程度。我们的假设是:将检测到广泛的个体间变异;并且某些药物组合对PHA刺激的PBMC具有协同抑制作用。细胞在补充有RPMI 1640的培养基中于37℃、5%二氧化碳-95%空气的湿润环境中培养65小时,通过在接下来的24小时内掺入3H-胸腺嘧啶来测量增殖反应。使用志愿者对照(n = 51)和透析患者(n = 23),在1×10^(-8)至10微克/毫升的10个FK浓度下评估PBMC增殖的抑制情况。在所测试的FK浓度范围内,FK抑制存在广泛的个体间变异性,在较高浓度下变异性较小。使用来自12名志愿者对照的PBMC评估FK与CyA、MP、6ME和MPA的相互作用。对于1×10^(-8)微克/毫升的FK;CyA、MP、6ME和MPA的使用浓度为0.01微克/毫升。对于1×10^(-7)微克/毫升的FK;CyA、MP、6ME和MPA的使用浓度为0.1微克/毫升。(摘要截短至250字)